Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.56 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.55 |
| ▸ | DTYMK | P23919 | 4/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.51 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654813 | 0.89 | DTYMK (0.59) | POLBPRMT5METTL3DTYMKP2RY1 | |
| SCHEMBL13552106 | 0.89 | DTYMK (0.59) | POLBPRMT5METTL3DTYMKP2RY1 | |
| SCHEMBL20906732 | 0.89 | POLB (0.56) | POLBDTYMKP2RY1ENPP1P2RX1 | |
| SCHEMBL18852775 | 0.89 | DTYMK (0.59) | POLBPRMT5METTL3DTYMKP2RY1 | |
| SCHEMBL12932267 | 0.89 | DTYMK (0.59) | POLBPRMT5METTL3DTYMKP2RY1 | |
| SCHEMBL23236495 | 0.89 | POLB (0.56) | POLBDTYMKP2RY1ENPP1P2RX1 | |
| SCHEMBL19033185 | 0.89 | POLB (0.60) | POLBDTYMKP2RY1ENPP1P2RX1 | |
| SCHEMBL10051912 | 0.89 | POLB (0.58) | POLBDTYMKP2RY1ENPP1P2RX1 | |
| SCHEMBL22327274 | 0.85 | POLB (0.52) | POLBDTYMKP2RY1ENPP1P2RX1 | |
| SCHEMBL10022247 | 0.85 | POLB (0.52) | POLBDTYMKP2RY1ENPP1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0710667-B1 | Modified oligonucleotides, their preparation and their use | ROCHE DIAGNOSTICS GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-6987177-B2 | Modified oligonucleotides, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-17 | — | — | US | disclosed |
| US-20030096981-A1 | Modified oligonucleotides, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-05-22 | — | — | US | disclosed |
| US-6479651-B1 | Modified oligonucleotides, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6150510-A | NUCLEOTIDES/NUCLEOSIDES WITH SUBSTITUTED 7-DEAZAPURINE BASE FORM MORE STABLE HYBRIDIZATION COMPLEXES; GENETIC PROBES; ANTISENSE AGENTS; GENE EXPRESSION INHIBITION; DIAGNOSTIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-21 | — | — | US | disclosed |
| EP-0710667-A2 | Modified oligonucleotides, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096981-A1 | Modified oligonucleotides, their preparation and their use | NSUN2, TYMP, ADAR | POLB 56/4885PRMT5 3151/4885METTL3 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.